Last quarter (Q2 2024), Immunovant's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Immunovant's net income was $-58.66M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 448.54M	$ 218.28M	$ 156.03M	$ 108.12M	$ 66.08M	$ 448.00
Operating Income	$ -268.56M	$ -218.28M	$ -156.03M	$ -108.12M	$ -66.08M	$ -448.00
Net Non Operating Interest Income Expense	$ 7.64M	$ 7.58M	-	$ 0.00	$ -625.00K	-
Other Income Expense	$ 916.00K	$ 253.00K	$ 781.00K	$ 328.00K	$ 412.00K	-
Pretax Income	$ -255.42M	$ -210.95M	$ -156.81M	$ -107.79M	$ -66.29M	$ -448.00
Tax Provision	$ -161.00K	$ 9.00K	$ -84.00K	$ -358.00K	$ 97.00K	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -255.26M	$ -210.96M	$ -156.73M	$ -107.43M	$ -66.39M	$ -448.00
Basic EPS	$ -1.97	$ -1.71	$ -1.43	$ -1.22	$ -1.54	$ 0.00
Diluted EPS	$ -1.97	$ -1.71	$ -1.43	$ -1.22	$ -1.54	$ 0.00
Basic Average Shares	$ 513.31M	$ 123.08M	$ 109.68M	$ 87.76M	$ 43.20M	$ 14.38M
Diluted Average Shares	$ 513.31M	$ 123.08M	$ 109.68M	$ 87.76M	$ 43.20M	$ 14.38M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 448.54M	$ 218.28M	$ 156.03M	$ 108.12M	$ 66.08M	$ 448.00
Net Income From Continuing And Discontinued Operation	$ -255.26M	$ -210.96M	$ -156.73M	$ -107.43M	$ -66.39M	$ -448.00
Normalized Income	$ -119.94M	$ -166.65M	-	$ -107.43M	$ -66.39M	$ -448.00
Interest Expense	-	-	-	$ 0.00	$ 625.00K	-
EBIT	$ -266.00M	$ -218.53M	$ -156.81M	$ -107.79M	$ -65.67M	$ -448.00
EBITDA	$ -264.63M	$ -217.21M	$ -155.58M	$ -107.72M	$ -65.64M	$ -448.00

Currency in USD

Immunovant Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing